Skip to main content

Table 1 Characteristics of the COPD and asthma patients

From: Molecular detection of respiratory pathogens and typing of human rhinovirus of adults hospitalized for exacerbation of asthma and chronic obstructive pulmonary disease

 

Subjects with acute exacerbation of COPD (n = 402)

Control COPD (n = 80)

p-value

(compared acute exacerbation and stable COPD)

Subjects with asthma exacerbation of (n = 100)

Control asthma (n = 21)

p-value

(compared acute and stable asthma)

Gender (Male)

367 (91.3%)

78 (97.5%)

0.03*

34 (34.0%)

12 (57.1%)

0.04*

Agea

77.4 ± 8.6

73.2 ± 7.4

0.00*

64.8 ± 17.7

48.0 ± 14.6

0.00*

Influenza vaccination in the last 12 months

150 (37.3%)

33 (41.2%)

0.50

26 (26.0%)

2 (9.5%)

0.15

Types of residence

  

0.00*

  

0.12

 Live alone

39 (9.7%)

4 (5.0%)

 

11 (11.0%)

0 (0.0%)

 

 Old age home resident

42 (10.4%)

0 (0.0%)

 

3 (3.0%)

0 (0.0%)

 

 Live with family

321 (79.9%)

76 (95.0%)

 

86 (86.0%)

21 (100.0%)

 

Current smokers

68 (16.9%)

18 (22.5%)

0.20

4 (4.0%)

2 (9.5%)

0.291

Medications before admission

 any ICS

317 (78.9%)

68 (85.0%)

0.14

76 (76.0%)

19 (90.5%)

0.12

 ICS with LABA

286 (71.1%)

66 (82.5%)

0.02*

65 (65.0%)

18 (85.7%)

0.05*

 LABA+LAMA

199 (49.5%)

75 (93.8%)

< 0.001*

30 (30.0%)

4 (19.0%)

0.23

Comorbidities

 Old tuberculosis

67 (16.6%)

9 (11.3%)

0.22

4 (4.0%)

0 (0.0%)

1.00

 Bronchiectasis

21 (5.2%)

2 (2.5%)

0.39

4 (4.0%)

0 (0.0%)

1.00

 Congestive heart Failure

36 (8.9%)

4 (5.0%)

0.24

9 (9.0%)

0 (0.0%)

0.35

 Ischaemic heart disease

38 (9.4%)

5 (6.2%)

0.35

7 (7.0%)

1 (4.7%)

1.00

 Hypertension

211 (52.4%)

29 (36.2%)

0.00*

39 (39.0%)

4 (19%)

0.08

 Hyperlipidaemia

65 (16.1%)

9 (11.2%)

0.26

17 (17.0%)

1 (4.7%)

0.19

 DM

79 (19.6%)

12 (15.0%)

0.33

19 (19.0%)

2 (9.5%)

0.52

 Osteoarthritis

8 (1.9%)

2 (2.5%)

0.67

4 (4.0%)

0 (0.0%)

1.00

Lung function

      

 Post-brochodilator FEV % predicted (%)a

45.8 ± 20.5

46.7 ± 17.6

0.71

73.8 ± 20.2

80.3 ± 22.6

0.23

 Post-brochodilator FEV1/FVC ratio (%)a

50.4 ± 15.5

47.1 ± 12.9

0.08

69.1 ± 11.6

74.9 ± 11.8

0.06

During Admission

 Symptoms

  Cough

347 (86.3%)

  

81 (81.0%)

  

  Wheeze

192 (47.8%)

  

62 (62.0%)

  

  Fever

133 (33.1%)

  

32 (32.0%)

  

  Runny nose

15 (3.7%)

  

9 (9.0%)

  

  SOB

380 (94.5%)

  

88 (88.0%)

  

  Sputum production

344 (85.6%)

  

74 (74.0%)

  

  Sore throat

31 (7.7%)

  

18 (18.0%)

  

  Chest pain

48 (11.9%)

  

9 (9.0%)

  

  Hemoptysis

6 (1.5%)

  

1 (1.0%)

  

Use of Non-invasive positive pressure ventilation

70 (17.4%)

  

5 (5.0%)

  

Use of invasive mechanical ventilation

1 (0.2%)

  

0 (0.0%)

  

Intensive care admission

2 (0.5%)

  

1 (1.0%)

  
  1. Data are presented as mean ± SDa or number (percentages)
  2. ICS inhaled corticosteroid, LABA long-acting beta-agonist, LAMA long-acting anti-muscurinic agent
  3. * p < 0.05